 the Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation (ADVANCE)112 trial all tested whether tight
control of serum glucose levels in diabetic patients would
reduce the risk for stroke. Despite achieving hemoglobin
A1C levels ⬍6.5%, no reduction in stroke risk was identified
in these trials. Glucose control to nearly normoglycemic
levels (target hemoglobin A1C ⬍